16726-66-2

Basic information

• Product Name: 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID
• Synonyms: 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID;3-BroMo-1-naphthlenecarboxylicacid;3-BroMo-1-naphthalenecarboxylic Acid;3-broMo-1-naphthoic acid;1-Naphthalenecarboxylic acid, 3-broMo-
• CAS NO: 16726-66-2
• Molecular Formula: C₁₁H₇BrO₂
• Molecular Weight: 251.08
• Mol File: 16726-66-2.mol

Chemical Properties

• Melting Point: 237-238 °C
• Boiling Point: 416.262 °C at 760 mmHg
• Flash Point: 205.548 °C
• Appearance: /
• Density: 1.649 g/cm³
• Storage Temp.: 2-8°C
• PKA: 3.09±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID(16726-66-2)
• EPA Substance Registry System: 3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID(16726-66-2)

Safety Data

• Hazardous Substances Data: 16726-66-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID is used as a key intermediate for the synthesis of a potent cholecystokinin (CCK) 1R receptor agonist. This agonist plays a crucial role in the modulation of the gastrointestinal system, aiding in the regulation of digestion, appetite, and other related processes.
Used in Chemical Synthesis:
3-BROMO-NAPHTHALENE-1-CARBOXYLIC ACID is also used as a building block in the synthesis of various chemical compounds, including dyes, pigments, and other specialty chemicals. Its unique structure and reactivity make it a valuable component in the development of new materials with specific properties and applications.

Upstream product

• 24050-49-5 3-bromonaphthalic-1,8-anhydride 
• 32018-86-3 3-aminonaphthalene-1-carboxylic acid 
• 81-84-5 1,8-Naphthalic anhydride 
• 6314-27-8 O-(hydroxymercuri)-1-naphtoic acid anhydride 

Downstream Products

• 16650-63-8 3-bromo-naphthalene-1-carboxylic acid methyl ester 
• 79996-92-2 (3-bromonaphthalen-1-yl)methanol 
• 79997-04-9 1-(bromomethyl)-3-cyanonaphthalene 
• 312922-25-1 3-(4-fluorophenyl)-1-naphthoic acid 
• 1354965-48-2 methyl 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-naphthoate 
• 1354965-50-6 3-(4-phenyl-1H-1,2,3-triazol-1-yl)-1-naphthoic acid 
• 1221565-73-6 4-(4-cyanonaphthalene-2-yl)benzoic acid methyl ester 
• 79996-86-4 3-bromonaphthalene-1-carbonitrile 
• 303779-66-0 3-bromo-1-naphthaldehyde 

Relevant articles and documents

NOVEL EP2 RECEPTOR AGONISTS

The compounds of formula (1), in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

COMPOUNDS FOR THE INHIBITION OF CELLULAR PROLIFERATION

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

RENIN INHIBITORS

Renin inhibitors, which are spirocyclic piperidine amides, of structural formula (I) and pharmaceutical compositions thereof useful in the treatment of cardiovascular diseases and renal insufficiency, wherein n, for each instance in which it occurs, is independently 0, 1, or 2; R1 is hydrogen, C1-6 -alkyl or C3-6 -cycloalkyl, wherein said C1-6 -alkyl or C3-6 -cycloalkyl group can be independently substituted with 1-3 halogens; A is (i) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic monocyclic ring or (ii) a five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring which is fused to another five- or six-membered saturated or unsaturated heterocyclic or carbocyclic ring, V is a bond or -(C=O)-, -CH(OH)-, -CH2- or =CH-; U is a bond or -CH2-, or for the case when V is =CH-, U is -CH=; X is =CH-, =CF-, =C(OR3)-, or -C=O-; and Y is =CH-, =CF-, =N-, or for the case when X is -C=O-, Y is -N(R3)-.

THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

NOVEL C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17

Two novel classes of non-steroidal substrate mimetics were synthesised and examined for their potency as inhibitors of human CYP17. Selected compounds were tested for inhibition of hepatic CYP enzymes 3A4, 1A2, 2C9 and 2C19. The most promising compound 15

A rapid, large-scale synthesis of a potent cholecystokinin (CCK) 1R receptor agonist

The development of a scalable synthesis of a potent cholecystokinin (CCK) IR receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support

The mercury-mediated decarboxylation (Pesci reaction) of naphthoic anhydrides investigated by microwave synthesis

The mercury-mediated decarboxylation (Pesci reaction) of several substituted naphthoic anhydrides has been investigated by microwave synthesis. A laboratory microwave reactor was found to be ideal for small-scale preparations of this slow reaction, reducing reaction times from typically four days to less than 1 h for the three-step process. The ionic reaction medium rapidly heated to high temperatures under microwave heating and could be efficiently maintained by low microwave power settings. Generation of stoichiometric CO2 was safely contained within the reaction tubes. A simplified reaction procedure has been developed. For substituted naphthoic anhydrides, 1H NMR analysis of the naphthoate ester derivatives indicated no change in the regioisomer ratio compared to previously reported thermal values.

A new approach to rapid parallel development of four neurokinin antagonists. Part 2. Synthesis of ZD6021 cyano acid

The manufacture of ZD6021 cyano acid (1) using a new project approach is described. Research Department processes were scaled up to 100 L if process safety anal robustness were not compromised; other factors were treated according to the new approach. By using this strategy, we were able to manufacture a key intermediate on sufficient scale to support delivery of 1 kg quantities of bulk drug within 6 months of the start of lab work.